What Analysts Are Saying About Valneva Stock
Ratings for Valneva (NASDAQ:VALN) were provided by 6 analysts in the past three months, showcasing a mix of…
Valneva Seeks Expanded Use For Its Chikungunya Vaccine In Adolescents With Encouraging Phase 3 Data
Valneva released positive Phase 3 data for its single-shot chikungunya virus vaccine in adolescents. The vaccine is also expected to be approved for use in Brazil.
Cracking The Code: Understanding Analyst Reviews For Valneva
In the last three months, 5 analysts have published ratings on Valneva (NASDAQ:VALN), offering a diverse range of…
Chikungunya Vaccine Maker Valneva Secures Non Dilutive Funding To Develop/Expand Its Clinical Pipeline
Valneva sells FDA Priority Review Voucher for $103 million after FDA approval of Ixchiq, the world's first licensed chikungunya vaccine. Proceeds to boost R&D projects.
McDonald’s, Caterpillar And 3 Stocks To Watch Heading Into Monday
With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Pfizer And Valneva Complete Recruitment For Phase 3 VALOR Trial For Lyme Disease Vaccine Candidate, VLA15
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA159,437* participants enrolled at sites across the U.S., Europe and Canada in areas where Lyme disease is
Expert Ratings for Valneva
Valneva (NASDAQ:VALN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Valneva Says Single Chikungunya Vaccine Shows Long-Lasting Antibody Response In Younger, Older Adults
Valneva SE (NASDAQ: VALN) reported antibody persistence data 24 months after vaccination with a single dose of its chikungunya vaccine IXCHIQ, further supporting the anticipated long-term durability of the immune response and in line with positive twelve-month persistence data the company reported
Analyst Ratings for Valneva
Over the past 3 months, 6 analysts have published their opinion on Valneva (NASDAQ:VALN) stock. These analysts are…
FDA Approves World’s First Mosquito-Borne Chikungunya Vaccine
The FDA approved Valneva SE's (NASDAQ: VALN) Chikungunya single-dose vaccine in individuals